NK510 cell therapy for advanced lung cancer after immunotherapy
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new natural killer (NK) cell therapy, NK510, for people with advanced non-small cell lung cancer who have already tried immunotherapy and it stopped working. The goal is to see if NK510 is safe and can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have advanced non-small cell lung cancer (stage III or IV) that cannot be removed by surgery or treated with radiation.
- Your cancer must not have certain gene changes (EGFR, ROS1, ALK), unless you have a different group in the trial.
- You must have tried at least 4 rounds of an immunotherapy drug (PD-1 or PD-L1 blocker) with or without chemotherapy, and your cancer got worse.
- You must have at least one tumor that can be measured on a CT or MRI scan.
- You must be in generally good health (ECOG score 0-2) and expected to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new natural killer (NK) cell therapy called NK510 for people with advanced gastric or colorectal cancer that has not responded to at least two prior treatments. The study aims to see if NK510 can help shrink tumors or slow the disease.
This trial tests a new immune cell treatment called NK521 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if this therapy can help shrink tumors, including in patients with liver cancer, ovarian cancer, or malignant ascites (fluid buildup in the belly with cancer cells).
This trial tests adding natural killer (NK) cell therapy to standard chemo and immunotherapy before surgery for stage IB to IIIA non-small cell lung cancer that can be removed. It aims to see if this combination helps shrink tumors and improve outcomes.
This trial tests whether a new drug combination (SYS6010 plus enlonstobart) works better than standard immunotherapy with chemotherapy for patients with advanced non-small cell lung cancer. You may qualify if you have not received prior cancer treatment and have a specific marker (PD-L1) on your tumor.
This trial tests an experimental immunotherapy called BNT116, given alone or with other drugs, for people with advanced non-small cell lung cancer (NSCLC). The goal is to see if it is safe and if it can help shrink tumors.
This trial tests an investigational natural killer (NK) cell therapy for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if these immune cells can shrink tumors and are safe.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.